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Abstract
Background: Heterotopic ossification (HO) is a significant problem for wounded warriors surviving high-energy
blast injuries; however, currently, there is no biomarker panel capable of globally characterizing, diagnosing, and
monitoring HO progression. The aim of this study was to identify biomarkers for HO using proteomic techniques
and blood serum.
Methods: Isobaric tags for relative and absolute quantitation (iTRAQ) was used to generate a semi-quantitative
global proteomics survey of serum from patients with and without heterotopic ossification. Leveraging the iTRAQ data,
a targeted selection reaction monitoring mass spectrometry (SRM-MS) assay was developed for 10 protein candidates:
alkaline phosphatase, osteocalcin, alpha-2 type I collagen, collagen alpha-1(V) chain isoform 2 preprotein, bone
sialoprotein 2, phosphatidate phosphatase LPIN2, osteomodulin, protein phosphatase 1J, and RRP12-like protein.
Results: The proteomic survey of serum from both healthy and disease patients includes 1220 proteins and was
enriched for proteins involved in the response to elevated platelet Ca+2, wound healing, and extracellular
matrix organization. Proteolytic peptides from three of the ten SRM-MS proteins, osteocalcin preprotein, osteomodulin
precursor, and collagen alpha-1(v) chain isoform 2 preprotein from serum, are potential clinical biomarkers for HO.
Conclusions: This study is the first reported SRM-MS analysis of serum from individuals with and without heterotopic
ossification, and differences in the serum proteomic profile between healthy and diseased subjects were identified.
Furthermore, our results indicate that normal wound healing signals can impact the ability to identify biomarkers, and
a multi-protein panel assay, including osteocalcin preproprotein, osteomodulin precursor, and collagen alpha-1(v) chain
isoform 2 preprotein, may provide a solution for HO detection and monitoring.
Keywords: Heterotopic ossification, SRM-MS, Osteocalcin, Osteomodulin, Collagen alpha-1(v)

Background
Heterotopic ossification (HO) is the formation of mature
lamellar bone in nonosseous (soft) tissues [1]. HO has been
associated with war injuries since World War I and is now
recognized as a significant comorbidity for wounded
warriors surviving high-energy blast injuries [1–3]. A study
of combat-related extremity injuries in Operation Enduring
Freedom (OEF) and Operation Iraqi Freedom (OIF) found
the risk of HO is highest following a blast mechanism injury and an amputation within the zone of injury [1]. HO
in the military population often results in chronic pain,
difficulties fitting prostheses, joint ankylosis, functional
limitations, prolonged rehabilitation, and substantial
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morbidity [4, 5]. Rates of HO in combat-related extremity
injuries are greater than 60% [1, 2].
In civilian populations, HO may occur after a traumatic event, including hip arthroplasty, distal humerus
fractures, spinal cord injuries (SCI), and closed brain
injuries [6]. The etiology of HO remains unknown, but
clinical risk factors include trauma, amputation, traumatic brain injury (TBI), SCI, thermal injury, major hip
arthroplasty, and other major orthopedic surgery [7].
The exact cellular events leading to HO are not yet
identified and as a result, treatment has been limited to
nonsteroidal anti-inflammatory (NSAID) drugs and local
radiation therapy used prophylactically. Many patients
require one or more surgical excisions of ectopic bone
[7]. Individuals with combat injuries often have additional diagnoses for which these prophylactic treatments

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Edsberg et al. Journal of Orthopaedic Surgery and Research (2017) 12:69

are contraindicated further limiting treatment options.
NSAIDs can cause severe gastrointestinal problems,
renal toxicity, and platelet deficiency. Similarly, radiation
therapy carries significant risks including fracture nonunion, genetic mutation, malignancy, and reproductive
organ damage. No current pharmaceutical treatment is
approved by the FDA to treat HO [7].
The etiology of HO is not well characterized. Aberrant
bone growth associated with the disease is diagnosed
using radiographs. In order to prevent the development
of HO, early detection of biomarkers associated misregulated wound healing mechanisms is necessary. Serum
is readily available and easily accessible for repeated
sampling for biomarker identification, and robust serum
biomarkers have been established for other disorders,
including cardiovascular disease [8]. The development of
HO requires a cell capable of bone production, an
osteoinducive factor, and an environment supportive of
osteoinduction [7]. Researchers have evaluated changes
in proteins associated with osteoinduction in the serum
following traumatic brain injury (TBI) in rats and
humans [9], and serum from TBI patients accelerated
the proliferation of osteoblastic differentiation in cells
from human muscle [10]. In contrast to blood serum,
tissue biopsy relative to the lesion samples are invasive
and location of the biopsy can impact results. Collectively,
this work supports the use of serum for the identification
of markers associated with the development of HO.
Recent advancements in mass spectrometry (MS)
technology have enabled proteomic analysis of complex
biological samples and have aided in the identification of
potential biomarkers in various diseases, including
evaluation of bone metabolism [11]. A high-throughput
MS technique, isobaric tags for relative and absolute
quantitation (iTRAQ), enables a global analysis of the
proteome differences between biological samples, which
provides the foundation for identifying potential biomarkers, but additional quantitative assays are required.
Proteomic differences identified using iTRAQ are
expressed as a ratio between samples and are therefore
relative and semi-quantitative. There are several quantitative assays available for protein biomarker analysis,
such as antibody approaches used in ELISAs or peptide
approaches used in advanced mass spectrometry assays.
Antibody-based approaches are limited based on reagent
specificity and availability, whereas a targeted MS assay
is limited only by the proteolytic and ionization characteristics of the protein of interest. One type of MS assay,
selection reaction monitoring (SRM-MS), is an advanced
proteomics technology enabling the identification and
precise quantification of peptides with high sensitivity,
specificity, and reproducibility [12, 13]. Analytical information from peptides obtained using SRM-MS allows by
inference, quantification of the corresponding proteins

Page 2 of 13

in complex biological samples. This technique is capable
of producing high-quality diagnostic data in disease processes [14] and is a more sensitive and reproducible
method for quantifying low-abundance proteins in complex biological samples. SRM-MS uses synthetic peptides
to optimize detection transition parameters for each
peptide target and as such is not an appropriate method
for a high-throughput proteomics analysis. The objectives of this study were to develop an SRM-MS assay
specific for overexpressed proteins present in the serum
of subjects with HO and test their predictive ability
using serum from subjects with and without HO.

Methods
Subject enrollment

This study was part of a larger project to study the
proteomics of HO in tissue and serum (manuscript in
preparation), focusing on mass spectrometry analyses
of serum samples from 41 subjects. Subjects were eligible
for enrollment in the study if they had or were being
treated for high-risk fractures, acetabular fracture, burns
with orthopedic injury, traumatic brain injury with
extremity trauma, undergoing amputation, and excision of ectopic bone or major arthroplasty. Subjects
below the age of 18 or currently being treated for
cancers or metastatic disease involving the bone were
excluded.
Study protocol and overview

Participants were enrolled prior to surgery, and outcome
was determined by evaluation of x-rays collected at the
time of surgery and during follow-up visits at 6 weeks,
12 weeks, 6 months, and 12 months. Blood (5 cm³) was
collected at time of the patient’s scheduled surgical procedure. Blood samples were collected into sterile vacutainer tubes with clot activator and gel for serum
separation. Serum was removed after 30 min to a sterile
screw top polypropylene tube and snap frozen in liquid
nitrogen before storage at −80 °C. Samples were
assigned to HO-positive or HO-negative group-based
disease status at the time of surgery and blood collection. Blood serum samples were pooled in equal volumes
by disease status and analyzed using iTRAQ. Individual
serum samples were analyzed for the abundance of specific proteins identified in the iTRAQ results using
SRM-MS, a targeted quantitative analysis (Fig. 1).
Sample and peptide preparation for iTRAQ

Reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise indicated. The top 14 most abundant proteins in the serum were depleted using the Seppro
IgY14 column systems: albumin, IgG, α2-antitrypsin, IgA,
IgM, transferrin, haptoglobin, α2-macroglobulin, fibrinogen, complement C3, α1-acid glycoprotein (orosomucoid),
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Fig. 1 Sample processing overview. A total of 41 serum samples were collected at time of surgery from subjects with (n = 10) and without (n = 31)
heterotopic ossification. Serum samples were pooled by disease state and subjected to an isobaric tag for relative and absolute quantitation (iTRAQ)
mass spectrometry (MS) analysis. The iTRAQ data was used to drive the selection of specific proteins to target via a selected reaction monitoring (SRM)
MS technique, a qualitative MS technique that enables the robust quantification of specific peptides within a single subject’s serum sample

HDL (apolipoproteins A-I and A-II), and LDL (mainly
apolipoprotein B). Serum samples were diluted 5× in IgY
dilution buffer, filtered (0.22 μm), and then injected into
IgY LC10 columns attached to an Agilent 1200 HPLC
system. The unretained fraction was collected.
In-solution depleted serum samples were further processed by MyOmicsDx, Inc (Towson, MD, USA) using
“filter-assisted sample preparation” (FASP) method
[15]. Briefly, protein samples in 9 M urea were reduced with
5 mM tris-(2-carboxyethyl) phosphine (TCEP) at 37 °C for
45 min and reduced cysteines were blocked using 50 mM
IAA at 25 °C for 15 min. Protein samples were cleaned
using 10 kDa Amicon Filter (UFC501096, Millipore) three
times using 9 M urea and two times using MyProt-Buffer 1
(MyOmicsDx, Inc). Samples were proteolyzed with trypsin
(V5111, Promega) for 12 h at 37 °C.
The peptide solution was acidified by adding 1%
trifluoroacetic acid (TFA) and incubated at room
temperature for 15 min. A Sep-Pak light C18 cartridge
(Waters Corporation) was activated by loading 5 mL
100% (vol/vol) acetonitrile and washed by 3.5 mL 0.1%
TFA solution two times. The acidified digested peptide
solution was centrifuged at 1800 × g for 5 min, and the
supernatant loaded into the cartridge. To desalt the
peptides bound to the cartridge, 1, 3, and 4 mL of 0.1%
TFA were used sequentially. To elute the peptides from
the cartridge, 2 mL of 40% (vol/vol) acetonitrile with
0.1% TFA was used. The eluted peptides were lyophilized overnight and reconstituted in 37 μL MyProtBuffer 3 (MyOmicsDx, Inc, Towson, MD, USA).
Multiplexed iTRAQ labeling

Digested peptides from samples in a volume of 37 μl
MyProt-Buffer 2 were labeled using 4-plex iTRAQ reagents (ABSciex, Framingham, MA, USA). After 2 h, labeled peptides were dried to remove organic solvents and

reconstituted in 500 μl MyProt-Buffer 3 (MyOmicsDx,
Inc, Towson, MD, USA), combined and fractionated on a
bRPLC (basic reverse phase liquid chromatography)
column (XBridge BEH C18 Column, 5 μm, 2.1 × 100 mm)
via XBridge BEH C18 Guard Column (Waters Corporation) using an Agilent 1260 HPLC system. Peptides in
each fraction were dried and re-suspended in 8 μl 0.1%
formic acid (EMD Millipore, Billerica, MA, USA) with 3%
acetonitrile for LC-MS/MS analysis.
A Sep-Pak light C18 cartridge (Waters Corporation)
was activated by loading 5 mL 100% (vol/vol) acetonitrile
(JT Baker) and was washed by 3.5 mL 0.1% TFA solution two times. Acidified digested peptide solution was
centrifuged at 1800g for 5 min, and the supernatant was
loaded into the cartridge. To desalt the peptides bound
to the cartridge, 1, 3, and 4 mL of 0.1% TFA were used
sequentially. To elute the peptides from the cartridge,
2 mL of 40% (vol/vol) acetonitrile with 0.1% TFA was
used, and this elution was repeated two more times for a
total of 6 mL of eluate. It was important to ensure that
the cartridge had stopped dripping before each sequential wash and elution solution was applied. The eluted
peptides were lyophilized overnight and reconstituted in
37 μL of MyProt-Buffer 2 (MyOmicsDx, Inc, Towson,
MD, USA).
Nanoflow electrospray ionization tandem mass
spectrometry analysis

Data-dependent MS/MS analyses of the iTRAQ-labeled
peptides were carried out by MyOmicsDx, Inc. (Towson,
MD) on a Q Exactive™ Hybrid Quadrupole-Orbitrap
Mass Spectrometer (https://www.thermofisher.com/us/
en/home.html) interfaced with Proxion nanoflow LC
system. Peptides were fractionated by reverse phase
HPLC on a 75 μm × 15 cm PicoFrit column packed with
Magic C18AQ (5 μm, 120 Å, https://www.bruker.com/)
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using 0–60% acetonitrile/0.1% formic acid gradient over
90 min at 300 nL/min. Eluting peptides were sprayed
directly into Q Exactive™ at 2.0 kV.
Survey scans (full MS) were acquired from 350 to
1800 m/z with up to 15 peptide masses (precursor ions)
individually isolated with a 2-Da isolation window and
fragmented (MS/MS) using a collision energy of 29%
and 30 s dynamic exclusion. Precursor and the fragment
ions were analyzed at 70,000 and 17,500 resolutions,
respectively. Peptide sequences were identified from
isotopically resolved masses in MS and MS/MS spectra
extracted with and without de-convolution using
Thermo Scientific MS2 processor and Xtract software.
iTRAQ-MS data processing

Mass spectrometry raw files were automatically processed through Proteome Discoverer 2.1 software using
Xtract and MS2-processor spectrum processor in
addition to default spectrum selector node. The data
was searched in Refseq 2015 human entries using Mascot search engine interfaced with different processing
nodes of Proteome Discoverer 2.1. Search parameters
included oxidation on methionine, iTRAQ 4-plex on
tyrosine, deamidation on residues N and Q as different
variable modifications, iTRAQ 4-plex on N-terminus
and lysine residue, and methylthio on cysteine residue as
different fixed modifications. Mass tolerances on precursor and fragment masses were set to 15 ppm and
0.03 Da, respectively. Peptide validator node was used
for peptide validation with stringent cutoff of 0.01 and
relaxed cutoff of 0.05 false discovery rate (FDR), and 1%
FDR cutoff was used to filter the data.
High confidence (0.1% FDR) and top ranked peptides
were considered with protein grouping options. Protein ratios were normalized through MyProt-QuantiR
(MyOmicDx, Inc) software package, and peptides with
>30% isolation interference were excluded from protein
quantification to avoid potential interference of reporter
ions from contaminant peaks. MA plots were used to
evaluate any potential bias between quantification channels within experiment and between experiments.
Proteomic bioinformatics analysis

The entire iTRAQ dataset, regardless of protein ratio,
was uploaded into Cytoscape v3.3.0 [16] and analyzed
using the ReactomeFI plugin (database 2015) [17] to
generate an interactome, followed by a pathway
enrichment analysis. Gene ontology enrichment analysis
for biological process, cellular component, and molecular function were completed using the cytoscape app
BiNGO [18] and REVIGO [19]. The iTRAQ ratio
(expression) data was overlaid with biological annotations to prioritize proteins for SRM analysis.
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Reagents SRM-MS

TCEP (tris-(2-carboxyethyl) phosphine) was purchased
from Thermo Scientific (Waltham, MA). LysC and trypsin proteases were purchased from Promega (Fitchburg,
WI). C18 Cartridges for sample preparation and chromatography columns for bRPLC and online HPLC of
Triple Quadrupole mass spectrometer were purchased
from Waters (Milford, MA). Acetonitrile was purchased
from JT Baker, and formic acid was obtained from EMD
Millipore (Billerica, MA, USA). MyProt-Buffer 1,
MyProt-Buffer 2, and MyProt-Buffer 3 were utilized by
MyOmicsDx, Inc (Towson, MD, USA). All other
reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise indicated.
SRM-MS data processing

Peptide samples reconstituted in 37ul MyProt-Buffer 3
(MyOmicsDx, Inc) were spiked with MyProt-SRM
Internal Control Mixture (MyOmicsDx, Inc) composed
of a pool of 1 f mole heavy isotope-labeled peptides covering a large hydrophobicity window and a large M/z
range (M/z 200 ~ 1300) and were subject to SRM analysis. Peptide samples were eluted through an online
Agilent 1290 HPLC system into the Jet Stream ESI
source of an Agilent 6495 Triple Quadrupole Mass
spectrometer.
Thirty peptides representing 10 proteins were chosen
as SRM targets from MyOmicsDx’s manually curated
SRM target peptide database, MyProt-SRM Map, based
on their iTRAQ ratio. Transition parameters and retention times of the 30 peptides were confirmed individually using an Agilent 6495 Triple Quadrapole Mass
Spectrometer for both doubly and triply charged precursor ions. Five or 6 transitions per peptide precursor were
selected for SRM analysis.
Three hundred and fifty sets of transition parameters
(corresponding to 30 peptides, representing the abundance of 10 proteins) and 30 SRM data files containing
the quantitative data of 30 peptides in 30 human serum
samples (Additional file 1) were imported into Skyline
3.1 [20]. The abundance of each target peptide was
represented by the total area under the curve (AUC) of
all its transitions normalized to the total AUC of all
transitions from the most nearby (sharing a similar
hydrophobicity) heavy isotope-labeled peptide from
MyProt-SRM Internal Control Mixture (MyOmicsDx,
Inc) spiked in before the SRM analysis. The abundance
of each target peptide was represented by the total AUC
of all its transitions normalized to the total AUC of each
control peptide’s transitions. The relative abundance
level of a target peptide in different samples was represented by its relative ratio to the abundance level of the
internal control peptide in the same sample. The abundance dataset was further normalized by the ratio
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obtained from a subject without HO, (ND-1), chosen
randomly as a reference disease negative sample in this
study. Differences in SRM peptide abundance were
tested using R and Welch’s t test.
Model construction

The dataset obtained from the SRM-MS assay was composed of 30 samples, 10 HO positive and 20 HO negative,
with 17 peptide abundance values for each sample. The
number of samples in this pilot study was limited, and the
number of parameters (p) for each subject (n) is relatively
large compared to the total number of samples (n = 30).
The SRM assay dataset was analyzed using three models,
random forest (RF), generalized linear model (GLM), and
support vector machine learning (SVM).
Random forest, originally proposed by Breiman in
1999, is an ensemble classification algorithm composed
of a series of decision trees. Each tree is built independently through a technique called “bagging” based on random selection of input variables. The prediction result is
based on the vote made by all trees. This modeling
approach provides a very accurate classifier, but it has
not been widely used in clinical diagnostics. In contrast,
logistic regression is a widely used standard regression
model for binary data. It has been widely used to
construct biomarker panels for clinical diagnostics.
Support vector machine learning is a supervised machine learning model that identifies the optimal separating hyperplane between two classes or states based
on least-squares regression of the data.
Seventy percent of the dataset was used to construct
models, and thirty percent of the dataset was withheld
to evaluate model performance. Resampling, regression,
and prediction were repeated 1000 times for each model.
Model performance was evaluated by comparing the
results generated from at least 100 predictions for each
of the three models, and the subset of models used to do
the prediction in each category were preselected with a
AUC of ROC no smaller than 0.98.
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HO-positive (n = 10) and HO-negative (n = 31) subjects.
No bias between biological or technical replicates was
observed, and median normalization was applied to the
raw data to allow direct comparison of the reported
ratios of the proteins between HO-positive and HOnegative groups. Collectively, 1220 unique proteins
(UniProtKB Accession) were measured, and a ratio per
protein was calculated between separately pooled HOpositive and HO-negative serum samples. The majority
of the proteins had an expression ratio between 0.5 and
1.5 (data not shown).
The interactome (Fig. 2) and subsequent pathway
enrichment analysis (Table 2) indicated extracellular
matrix organization, ECM-receptor interaction, response
to elevated platelet cytosolic Ca+2, and complement and
coagulation cascades were enriched. The gene ontology
biological process enrichment analysis included response
to wounding, acute inflammatory response, and activation of plasma proteins involved in acute inflammatory
response as top enriched biological processes (Fig. 3;
and Additional file 2).
In total, 10 candidate proteins were selected for SRMMS from the iTRAQ studies based on relative fold
changes in iTRAQ ratios and the characteristics of the
proteotypic peptides for each protein (Table 3). Eight proteins, osteomodulin (OMD), collagen alpha-2(l) chain precursor (COL1A2), collagen alpha-1(V) chain isoform 2
preprotein (COL5A1), alkaline phosphatase (ALPL), phosphatidate phosphatase LPIN2 (LPIN2), RRP12-like protein
(RRP12), TRAF3-interacting protein 1 (TRAF3), and protein phosphatase 1J (PPM1J), were selected from the
serum iTRAQ results and subsequent bioinformatics analysis. Two additional proteins, bone sialoprotein 2 precursor (IBSP) and osteocalcin preprotein (BGLAP), were
selected from an iTRAQ survey of tissue samples from
HO-positive and HO-negative samples from the same
study subjects because the ratio reported from the tissue
data suggested a significant increase of this protein in the
disease state compared to non-disease (manuscript in
preparation).

Results
iTRAQ results
Proteomics analysis and serum biomarker selection

In total, 41 subjects including 27 men and 14 women
ranging in age from 22 to 83 were enrolled (Table 1).
HO-negative samples were derived largely from total hip
arthroplasty (ages 28–83) in both male and female subjects ages 22–83. All HO-positive samples were collected
during HO excision or hip revision procedures in men
and women ages 22–40. Serum samples were analyzed
via qualitative proteomics analysis and/or a targeted
quantitative analysis (Fig. 1). The high-throughput proteomics analysis consisted of a 4-plex iTRAQ experiment,
which utilized separately pooled serum samples from

SRM analysis

SRM transition parameters of all 30 peptides targeting
the top overexpressed proteins quantified by iTRAQ
were incorporated into a SRM-MS assay method. Each
protein was independently quantified by 3 peptides in 30
individual patient serum samples. Seventeen peptides
representing 9 of the 10 proteins from the initial experimental design, alkaline phosphatase, osteocalcin, alpha-2
type I collagen, collagen alpha-1(V) chain isoform 2 preprotein, bone sialoprotein 2, osteomodulin, protein
phosphatase IJ, and RRp12-like protein, were validated
as SRM targets after successfully being detected and
quantified in serum (Additional file 3). Phosphatidate
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Table 1 Surgical procedures and heterotopic ossification status of serum samples
HO negative

HO positive

Subjects

M

F

Age

Subjects

M

F

Age

All

31

18

13

22–83

10

9

1

22–40

Total hip arthroplasty (THA)

18

10

8

28–83

–

Open reduction and internal fixation (ORIF)

7

5

2

26–64

–

Hip revision (HR)

3

3

45–62

2

1

1

36–40

HO excision (HOE)

–

8

8

Other

3

3

22–36

22–31

–

A total of 31 serum samples were collected from subjects (18 male and 13 female) with wounds but no signs of disease, heterotopic ossification negative (HO−).
A total of 10 serum samples were collected from heterotopic ossification positive (HO+) subjects (9 male and 1 female). Serum samples were collected at time of
surgery. The surgical procedure (or wound) differed between subjects, with the most common procedures being total hip arthroplasty (THA), open reduction and
internal fixation, hip revision, and HO excision. Subjects ranged in age from 22 to 83 years old

phosphatase LPIN2 isoform X2 was detectable only by
one peptide in five HO− and five HO+ samples and was
dropped from the panel.
The RF, GLM, and SVM algorithms produced predictive models that were comparable in performance (Fig. 4),
but RF predictions were closest to the true disease state
for 9 of the 10 HO+ subjects (binary value where 0 indicates HO negative or non-disease (ND) and 1 indicates
HO positive or disease (D)) (Fig. 4). Using the RF generated model, the SRM peptides were ranked by the mean
square error (MSE) increase if the peptide is randomly
permuted. If a peptide is an important predictor, then

a

the model fit decreases when it is randomly permuted
and the overall MSE increases. Peptides SRM-8, SRM13, SRM-4, SRM-5, and SRM-6 representing proteins
osteocalcin preprotein, osteomodulin precursor, and collagen alpha-1(v) chain isoform 2 preprotein were identified as potential biomarkers for HO (Fig. 5).
Relative expression levels of the peptide biomarkers
were significantly different for SRM peptides, SRM-4,
SRM-5, SRM-6, SRM-13, SRM-14, SRM-8, SRM-3,
SRM-23, derived from osteocalcin, collagen alpha-1(V)
chain, osteomodulin, bone sialoprotein 2, and RRP12like protein (Fig. 6). Three osteocalcin peptides (SRM4,

b

Fig. 2 ReactomeFI analysis of iTRAQ data from serum samples. a Workflow pathway enrichment analysis iTRAQ data. All proteins quantified in the
iTRAQ experiment, regardless of the disease state, were uploaded in cytoscape via ReactomeFI application. Genes were clustered based on pathway
and sub-network annotations. A pathway enrichment analysis indicated that 90 pathways were enriched within the proteomic space of serum samples.
b Reactome analysis serum samples. Proteins were clustered using ReactomeFI, and 13 major modules were identified. A pathway enrichment analysis
was completed for each module using an FDR >0.01
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Table 2 Pathway enrichment summary iTRAQ data
Biological pathway

Pathway database

Ratio

Pathway proteins

Dataset proteins

p value

FDR

Extracellular matrix organization

R

0.0243

248

64

1.11E−16

1.30E−14

ECM-receptor interaction

K

0.0085

87

31

1.11E−16

1.30E−14

Response to elevated platelet cytosolic Ca

R

0.0081

83

45

1.11E−16

1.30E−14

Complement and coagulation cascades

K

0.0068

69

46

1.11E−16

1.30E−14

Beta1 integrin cell surface interactions

N

0.0065

66

27

1.11E−16

1.30E−14

Formation of fibrin clot (clotting cascade)

R

0.0038

39

24

1.11E−16

1.30E−14

Focal adhesion

K

0.0203

207

37

8.46E−12

8.46E−10

Staphylococcus aureus infection

K

0.0054

55

18

2.67E−10

2.35E−08

2+

Beta3 integrin cell surface interactions

N

0.0042

43

16

4.32E−10

3.37E−08

L1CAM interactions

R

0.0077

79

20

2.15E−09

1.38E−07

All proteins quantified in the iTRAQ experiment, regardless of the disease state, were uploaded in cytoscape via ReactomeFI application. A pathway enrichment
analysis was executed for the entire reactome
R Reactome, K KEGG, N NCI PID

5, and 6) had similar patterns between the disease and
non-disease state, supporting a higher abundance in HO+
compared to HO−. Collagen alpha 1 (SRM13, 14, 15) had
two peptides (SRM13 and 14) that support this protein in
higher abundance in HO, whereas SRM15 showed no
difference between HO− and HO+. Two peptides were
measured for osteomodulin (SRM7 and 8), and both
peptides were elevated in HO+ compared to HO−. Two peptides were measured for alkaline phosphatase (SRM17 and
18), and SRM18 had greater dispersion in the upper quartile
in HO+ compared to HO−. A single peptide was measured
for bone sialoprotein (SRM3), and the data support higher
peptide abundance in HO+ compared to HO−. A single
peptide was measured for RRP12 (SRM 23) and demonstrated greater dispersion in expression in HO+ versus HO−
samples. One peptide was quantified for TRAF3 (SRM27),
which showed no difference between HO+ and HO−.

Protein-protein interactions between SRM candidates
were identified by ReactomeFI (Fig. 7) such that their
connections with each other (panel a) and within the
context of differentially regulated proteins in iTRAQ
experiment (panel b) could be analyzed. Of interest, six
of the SRM candidates, BGLAP, COL1A2, COL5A1,
IBSP, LPIN2, and OMD, were clustered together using
linker regions and are involved in extracellular matrix
organization and ECM-receptor interaction (panel a).
When these candidates were examined in conjunction
with other differentially regulated proteins, response
to elevated platelet cystosolic Ca+2 sub-network was
enriched (panel b). Collectively, these data suggest
that there are several sub-networks, which are highly
connected through protein-protein interactions that
contain proteins that are differentially expressed in
HO.

Fig. 3 Gene ontology enrichment analysis iTRAQ data. All proteins quantified in the iTRAQ experiment regardless of the disease state were uploaded
into cytoscape via BiNGO. BiNGO results were analyzed via REVIGO (reduce and visualize gene ontology)
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Predicted: alkaline phosphatase,
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isoform X3 [Homo sapiens]
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Collagen alpha-2(I) chain
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Protein serine/threonine phosphatase activity
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integrin binding [GO:0005178]; metal ion
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integrin binding [GO:0005178]; metal ion
binding [GO:0046872]; platelet-derived growth
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binding [GO:0043394]

Calcium ion binding [GO:0005509];
hydroxyapatite binding [GO:0046848];
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Gene ontology: molecular function

Gene ontology: cellular component

integral component of membrane [GO:0016021]; nuclear
membrane [GO:0031965]; nucleolus [GO:0005730]

Cytosol [GO:0005829]; endoplasmic reticulum membrane
[GO:0005789]; nucleus [GO:0005634]

Anchored component of membrane [GO:0031225];
extracellular exosome [GO:0070062]; extracellular
membrane-bounded organelle [GO:0065010];
extracellular space [GO:0005615]; integral component
of membrane [GO:0016021]; membrane [GO:0016020];
plasma membrane [GO:0005886]; proteinaceous
extracellular matrix [GO:0005578]

Basement membrane [GO:0005604]; collagen type V
trimer [GO:0005588]; endoplasmic reticulum lumen
[GO:0005788]; extracellular exosome [GO:0070062];
extracellular matrix [GO:0031012]; extracellular region
[GO:0005576]

Basement membrane [GO:0005604]; collagen type V
trimer [GO:0005588]; endoplasmic reticulum lumen
[GO:0005788]; extracellular exosome [GO:0070062];
extracellular matrix [GO:0031012]; extracellular region
[GO:0005576]

Extracellular exosome [GO:0070062]; extracellular
region [GO:0005576]; extracellular space [GO:0005615];
Golgi lumen [GO:0005796]; lysosomal lumen
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[GO:0005578]

Cytoplasm [GO:0005737]; dendrite [GO:0030425];
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Peptide ID

Peptide sequence

AVEEGLTYK

SRM-28
SRM-29
SRM-30

AIIVR
ASFSRPTFLQLSPGGLR
SPDLPNAASAPPAAAPEAPR

YLHDIITEVIR
ISFLQK
ITDCAVEPLK

SRM-24
SRM-25
SRM-26
SRM-27

FGFELVK
AAQHGVCSVLK

SRM-22

GLEPEVAALYFPK
VDSPSK
VIPSEDNLISEVEK

GFFLLVEGGR
ANEGTVGVSAATER
LDGLDLVDTWK

VLDFHNLPDGITK
DAQLSAPTK
QLYPASAFPEDFSILTTVK

GPAGPSGPAGK
GEIGNPGR
AQPENIPAK

IDYGVFAK
LLLGYNEISK
NLEHLYLQNNEIEK

YLYQWLGAPVPYPDPLEPR
GAAFVSK
QEGSEVVK

HAYFYPHLK
IEDSEENGVFK
AYEDEYSYFK

SRM-23

SRM-19
SRM-20
SRM-21

SRM-16
SRM-17
SRM-18

SRM-13
SRM-14
SRM-15

SRM-10
SRM-11
SRM-12

SRM-7
SRM-8
SRM-9

SRM-4
SRM-5
SRM-6

SRM-1
SRM-2
SRM-3

Ten proteins were chosen for selected monitoring reaction (SRM) MS analysis based on iTRAQ data. Three peptides per protein were synthesized for assay development, and the molecular function and cellular component
gene ontologies for each SRM candidate were annotated

GI accession number

Gene

Table 3 iTRAQ proteomics directed SRM candidate selection

Edsberg et al. Journal of Orthopaedic Surgery and Research (2017) 12:69
Page 8 of 13

Edsberg et al. Journal of Orthopaedic Surgery and Research (2017) 12:69

Page 9 of 13

Fig. 4 Summary of model comparison SRM assay. Samples were annotated as either disease state (heterotopic ossification positive—HO+) or
non-disease (ND) state (heterotopic ossification negative—HO−). Three different statistical models were utilized to analyze the SRM-MS data:
random forest (RF; red line), generalized linear model (GLM; green line), and support vector machine learning (SVM; purple line). A non-disease
state for HO− prediction was 0 (blue line left panel) and a disease state for HO+ prediction was 1 (blue line right panel). All three statistical models
performed similarly

Fig. 5 Mean square error analysis for random forest model. Using the random forest (RF) model, peptides with a mean square error (MSE) increase >8
were considered important variables because random permutation of these variables had a significant impact on the model prediction of disease state
versus non-disease state
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Fig. 6 Box-whisker plots for selection reaction monitoring peptide candidates for heterotopic ossification (HO+/D) and non-disease (HO−/ND)
serum samples. Distribution of selection reaction monitoring (SRM) normalized abundance ratios for each peptide for heterotopic ossification
negative samples (non-disease; ND) and heterotopic ossification positive samples (disease; D)

Discussion
The presence of HO is determined using radiographs,
which limits the ability to predict patients that are susceptible to HO and complicates early diagnosis of the
disease as aberrant bone formation must first be detectable. Furthermore, using tissue samples to identify early
signs of HO can be difficult because the proteome of
tissue within a wound bed can vary widely depending on
location within the wound bed [21]. Using tissue for
disease identification requires invasive sampling and like
all biopsy results, is dependent on the location of the
sample in relation to the suspected disease foci.
A biomolecular screening tool using serum from
wounded patients could allow for earlier diagnosis, intervention, and the potential development of novel therapeutics, to prevent development of HO [2, 9]. A major
challenge with identifying systemic markers is the need
for data-driven approaches. Applying a priori knowledge
limits the advancement of screening assays because the
majority of protein candidates, for example, MMPs are
involved in normal healing and disease processes [22].
Effective diagnostic panels require multiple biomarkers

across different gene families because the disease state is
more often a consequence of misregulation of protein
expression rather than a single mutation of a critical
protein.
Another challenge for devising a pharmaceutical treatment for HO is the lack of knowledge regarding metabolic processes and misregulated cellular signaling
events underlying the disease. Since HO has similar
characteristics as seen in the normal physiology of
fracture healing, treatment options for HO need to be
very specific to avoid impairment of normal bone healing [22]. Identifying biomarkers that allow for early identification of HO is confounded by the active and
ongoing inflammatory response present due to injury.
During the inflammatory phase of the wound healing
process, without the formation of heterotopic ossification, there will be a strong signal in the biological space
of proteins related to wound healing.
Utilizing a shotgun proteomics assay, iTRAQ, qualitative expression levels were determined for all detectable
proteins (1220) from serum samples collected from HO
+ and HO− subjects and used to identify proteins that
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Fig. 7 Summary target candidates for selection reaction monitoring assay. a The 10 proteins used in the selection reaction monitoring (SRM)
assay were analyzed via ReactomeFI in cytoscape. Six of the candidates (circles) were clustered with six linker genes (diamonds). Relevant
pathways for wound healing and ossification within this small interactome were extracellular matrix organization and extracellular matrix-receptor
interaction. b The 10 proteins (red nodes) used in the selection reaction monitoring (SRM) assay were analyzed via ReactomeFI in cytoscape with all
proteins that were differentially regulated (green nodes) in the iTRAQ experiment

are differentially regulated between the disease and nondisease state. This global proteomics approach enabled a
data-driven methodology. The bioinformatics analyses
built networks of functionally related proteins capable of
identifying crosstalk through protein-protein interactions
between sub-networks. The goal of this approach was to
identify biomarkers, proteins linked to misregulated
pathways and that are differentially expressed in the disease state compared to non-disease state. The current
research found that serum from both healthy and
disease patients is enriched for proteins involved in the
response to elevated platelet Ca+2, wound healing, and
extracellular matrix organization, and that these pathways
include proteins that are differentially regulated in the
disease state (Table 2).
Shotgun proteomic techniques including iTRAQ provide a knowledgebase for identifying potential clinical
biomarkers without the need for a priori knowledge, but
results are semi-quantitative and require follow-up validation using a quantitative assay. To transition the semiquantitative iTRAQ results into a clinical diagnostic
system, we developed and utilized SRM-MS assays to
precisely and robustly quantify 10 proteins chosen based
on expression ratios from the iTRAQ experiment combined with functional annotations, including gene

ontology and pathway information. Using a random forest model and the SRM-MS data, osteocalcin preproprotein, osteomodulin precursor, and collagen alpha-1(V)
chain isoform 2 preprotein were determined to be the
best candidates for predicting the disease state (HO+).
The model predictions of these targets as diagnostic
markers are supported by a study of osteoclast and
osteoblast activity after total hip arthroplasty, which
found that osteocalcin increased in individuals who
developed HO [23]. Osteocalcin (gene BGLAP; P02818)
is secreted by bone-forming osteoblasts [24], and a
strong overexpression of osteocalcin mRNA in HO
isolated cells has been observed [25]. The wound fluid
from blast-injured patients has osteoinductive signaling
properties [5]. Serum from patients with TBI induced an
increase in skeletal muscle cells, and the high levels of
alkaline phosphatases suggested an increased osteogenic
capability [10].
Bone formation and remodeling require a balance
between osteoclast and osteoblast activity [26]. Osteomodulin (OMD), or osteoadherin, is part of the leucinerich repeat proteins (SLRPs) located in the extracellular
matrix. OMD is expressed by osteoblasts and is involved
in the regulation of bone formation [27]. OMD has also
been shown to regulate the diameter and shape of
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collagen fibrils [28]. The SRM findings presented here
for both osteocalcin and osteomodulin in HO are consistent with the cell data from resected human HO bone
that expressed the osteoblast phenotype (type I collagen)
[29]. Other investigators have reported that collagen
expression was increased in tissue from wounds with
HO for COL10A1, COL4A3, and COL11A1 [4, 30].

Conclusions
This study is the first reported SRM-MS analysis of serum
from individuals with and without heterotopic ossification.
Differences in the serum proteomic profile between healthy
and diseased subjects were identified. Furthermore, our results indicate that normal wound healing signals can impact
the ability to identify biomarkers, and a multi-protein panel
assay, including osteocalcin preproprotein, osteomodulin
precursor, and collagen alpha-1(v) chain isoform 2 preprotein, may provide a solution for HO detection and
monitoring. The proteomic analysis within this report
focuses on protein abundance, ignoring protein posttranslational modifications (PTM). Of interest, osteocalcin
has several amino acid residues that are susceptible to
PTM that influence the function of this protein [31].
Future studies are planned to identify the presence and
potential of differentially regulated PTMs in HO.
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